The use of metagenomics for virus discovery in clinical samples has opened new opportunities for understanding the aetiology of unexplained illness. This study explores the potential of this sequence-independent approach in a public-health setting, by systematic analysis of samples cultured from patients with unexplained illness through a combination of PCR-based assays and viral metagenomics. In total, 1834 cell-culture isolates were collected between 1994 and 2007 through the Enterovirus Surveillance programme in the Netherlands. During the 13 year period, seven samples that exhibited reproducible cytopathogenic effects in cell culture tested negative in standard PCR assays for a range of viruses. In order to fill the diagnostic gap, viral metagenomics was applied to these culture supernatants, resulting in the rapid identification of viruses in all of the samples. The unexplained samples contained BK polyomavirus, herpes simplex virus, Newcastle disease virus and the recently discovered Saffold viruses (SAFV) (which dominated the unexplained samples; n54). The full genomic sequences of four SAFV genotype 3 (SAFV-3) viruses, which share 88-93 % nucleotide identity with known SAFV-3 viruses, are reported. Further screening for SAFV in additional cultured, unidentified clinical isolates from 2008 and 2009 resulted in identification of another SAFV-positive sample. Although the pathogenicity of the identified viruses has not been established, this study demonstrates that viral metagenomics is a powerful tool that can be integrated into public-health monitoring efforts to investigate unidentified viruses in cell cultures from clinical isolates where standard PCR assays fail to detect viruses.
INTRODUCTION
Diagnostic assays for pathogen detection are a critical component of public-health monitoring efforts. The detection and identification of viruses in clinical samples rely on a range of traditional and modern techniques (Leland & Ginocchio, 2007) . Traditionally, electron microscopy and cell culture have been used to identify the presence of viral agents. These traditional techniques have now been combined or replaced by molecular or serological assays designed to screen for specific 'known' viruses. Subsequently, if no viral pathogens are found, more investigative methods, such as generic PCR assays that target viral groups rather than species-specific assays, are used (Svraka et al., 2007 (Svraka et al., , 2009a . The combination of these molecular techniques is often successful, but fails to produce conclusive results when novel viruses or divergent variants of a known virus family are involved. Moreover, viruses do not have ubiquitously conserved genetic elements such as ribosomal RNA that can be used to amplify and identify all viruses and, thus, there is no universal PCR assay that can target all viruses in a sample (Rohwer & Edwards, 2002) . As novel viruses are discovered frequently, there is a need to constantly update PCR assays (Abed & Boivin, 2008; Allander et al., 2005; van der Hoek et al., 2004) . In view of the limitations of methods that target specific viruses, new approaches are required for the identification of novel or 'unsuspected' viruses in publichealth monitoring schemes. One promising approach for rapid virus identification is the use of virus purification and metagenomic sequencing (viral metagenomics). viral metagenomics, where viruses are purified before sequencing and yield of viral sequences is high (Thurber et al., 2009) , from a direct metagenomics approach, where total homogenates are sequenced and viruses account for only a small proportion of the sequences (Cox-Foster et al., 2007) . Viral metagenomics has been used to characterize virus communities present in the environment (Angly et al., 2006; Breitbart et al., 2004; Dinsdale et al., 2008; Djikeng et al., 2009) and to describe viruses in mammalian (including human) faeces (Blinkova et al., 2010; Breitbart et al., 2003 Breitbart et al., , 2008 Cann et al., 2005; Li et al., 2010; Victoria et al., 2009; Zhang et al., 2006) , cell culture (Jones et al., 2007; Kapoor et al., 2008) , respiratory-tract aspirates (Allander et al., 2005; Willner et al., 2009 ) and blood (Breitbart & Rohwer, 2005; Jones et al., 2005) , and animal tissues (Ng et al., 2009a, b) .
The present study describes the use of a combination of molecular approaches, including specific and generic PCRs for various viruses as well as metagenomic sequencing, to identify viruses from clinical specimens in a public-health context. Virological data from 1834 cultured clinical specimens collected between 1994 and 2007 through the Enterovirus Surveillance (EVS) programme in the Netherlands are summarized. Metagenomic sequencing led to the identification of viruses in all samples that exhibited consistent cytopathogenic effects (CPE) and remained unexplained after PCR testing.
RESULTS

Characterization of isolates from enterovirus surveillance at RIVM
From 1994 to 2007, a total of 1834 cell-culture isolates were submitted to the RIVM to identify viruses in cell cultures with CPE. Upon passaging at RIVM, 92 cell-culture isolates did not show reproducible CPE on cell lines and thus were not investigated further (Table 1) . Of the 1742 samples with reproducible CPE, 1513 were confirmed as being enterovirus-positive and 189 as parechovirus-positive. Extended PCR testing resulted in the identification of other viral agents, such as adenoviruses, reoviruses, rhinoviruses and astroviruses, in 33 cell-culture samples (Table 1) . The seven remaining cell-culture samples exhibiting consistent CPE tested negative for all viral PCR assays and were processed for viral metagenomics (Table 2) .
Viral metagenomics of cell-culture samples with unidentified viruses
Viral metagenomics was performed on seven cell-culture samples where PCR assays failed to identify potential viral pathogens (Table 2 ). This approach allowed the identification of viral agents in all samples with minimal sequencing (,50 clones per sample). Viral sequences from four of the cell cultures were related to the recently discovered Saffold viruses (SAFV). The other unexplained cell-culture samples contained a paramyxovirus related to Newcastle disease virus (one isolate, to be described elsewhere), BK polyomavirus (one isolate) and herpes simplex virus (one isolate) ( Table 2) . Sequences related to BK polyomavirus and herpes simplex virus were 100 % identical at the nucleotide level to known virus sequences and were not examined further. As SAFV-like sequences were identified in four isolates, the complete genomes of these viruses were sequenced. The genomes were identified as SAFV_NL1999-590, NL2007-2686, NL2007-2690 and NL2005-1035 (GenBank accession nos HM181996-HM181999, respectively). These isolates represent samples collected between 1999 and 2005 (Table 2) .
Phylogenetic analysis of identified SAFV
Available SAFV complete or near-complete genome sequences were used for phylogenetic analysis (Fig. 1) . All of the SAFV isolates from EVS samples clustered with SAFV genotype 3 (SAFV-3) genomes from the Netherlands and Germany. A similarity-plot analysis (using SimPlot software; see Methods) was performed to evaluate sequence similarities among the different SAFV genotypes (Fig. 2) . SAFV-3_NL2007 (GenBank accession no. FM207487) was selected as the query sequence to evaluate how the new genomes compared with this genome, which was discovered in the Netherlands from a stool sample collected in 2007 (Zoll et al., 2009) . The SAFV_NL2007-2686, NL2007-2690 and NL2005-1035 isolates were almost identical to each other, sharing 98-99 % nucleotide identity. The SAFV_NL1999-590 isolate showed the lowest sequence similarity to SAFV-3_NL2007 and the other SAFV-like genomes detected in this study (88 % overall nucleotide identity to all SAFV isolates from the Netherlands). The region encoding the structural protein of the SAFV_NL1999-590 genome showed the most divergence from other SAFV-3 sequences, including those from Germany (Fig. 2) . NL1999-590 shared between 80 and 87 % nucleotide identity with the query sequence, whilst the other SAFV-3 genomes, including those from To further describe the five SAFV-like viruses identified in samples from the EVS programme, complete VP1 sequences were acquired and used for classification. Phylogenetic analysis using a neighbour-joining tree was performed on approximately 825 nt of the VP1 protein gene (Fig. 3) . All of the detected SAFV clustered with SAFV-3 sequences from the Netherlands, California and Germany ( Fig. 3 ) (Chiu et al., 2008; Drexler et al., 2008; Zoll et al., 2009 ).
DISCUSSION
RIVM is a poliovirus reference laboratory, to which laboratories across the Netherlands submit cell-culture isolates for confirmation and typing of enteroviruses through PCR assays and serological testing. This programme started in 1994, after a poliovirus type 3 outbreak in 1992-1993, to monitor the eradication of poliovirus from the Netherlands (Conyn-van Spaendonck et al., 1996; Oostvogel et al., 1994) . For samples collected between 1994 and 2007, RIVM confirmed the presence of a range of known viruses in all but seven samples. Enteroviruses (including human rhinoviruses) accounted for 82.5 % of the samples, and parechoviruses were the second most common group of viruses detected, accounting for 10.3 % of the samples collected through EVS (van der Sanden et al., , 2009 . Extended PCR testing allowed the identification of other viruses in a low proportion of samples (,1 % for each virus). Finally, viral metagenomics enabled the identification of additional DNA and RNA viruses in all of the remaining unexplained samples. Of note, none of these were enteroviruses, indicating that the existing enterovirus PCR assays effectively capture the diversity of enteroviruses circulating in the Netherlands.
As expected, two genera from the family Picornaviridae, Enterovirus and Parechovirus, comprised the bulk of viruses detected during the 13 year EVS period investigated in this study. The newly described SAFV dominated the unexplained cases (approx. 33 % of the cell cultures with unidentified viruses from 1994 to 2009), and also belong to the family Picornaviridae, but to a third genus, named Cardiovirus.
Since its initial discovery in 2007 from a stool sample collected in 1981 in California, USA (Jones et al., 2007) , SAFV has been detected in stool and respiratory samples from patients in Europe, North and South America and Asia (Abed & Boivin, 2008; Blinkova et al., 2009; Chiu et al., 2008; Drexler et al., 2008; Liang et al., 2008; Ren et al., 2009; Xu et al., 2009; Zoll et al., 2009) . Currently, there are eight SAFV genotypes based on variants of the VP1 protein (SAFV-1-8), which is a determinant of viral tropism and antibody-neutralization sensitivity . To date, most of the SAFV diversity has been identified from samples collected in Pakistan, where genotypes 2-6 and 8 have been identified . In contrast, SAFV-3 is the only genotype that has been detected in samples collected in the Netherlands, both previously (Zoll et al., 2009 ) and in our study.
One of the SAFV-3 genomes, SAFV_NL1999-590, is divergent in the structural protein-encoding region of the genome from other SAFV-3 genomes, but conservation of amino acids in this region suggests that SAFV_NL1999-590 belongs to the same genotype (Fig. 4) . It is possible that the divergence observed in SAFV_NL1999-590 is due to mutational changes over time, indicating prolonged circulation of these viruses, as has been described for other enteroviruses (van der Sanden et al., , 2009 . As there are limited data regarding SAFV-3 isolates, it is difficult to calculate their substitution rates. Alternatively, SAFV_NL1999-590 may be recombinant relative to genotype 3 strains from the USA, as the VP1 phylogenetic analysis indicated that SAFV_NL1999-590 clusters with SAFV-3 strains from California instead of strains from the Netherlands and Germany. Within-genotype recombination has been reported for SAFV-2 (Drexler et al., 2010) , but BootScan analysis failed to show evidence for recombination between SAFV_NL1999-590, SAFV-3 sequences from the Netherlands and Germany, and SAFV-1 and -2 sequences from California, Canada and Brazil (data not shown). For definitive conclusions, more completegenome sequences of SAFV strains identified in the USA are needed.
The identification of different SAFV-3 isolates in 0.25 % of the tested samples is in the same range as other viruses Fig. 1 . Neighbour-joining phylogenetic tree of complete or near-complete SAFV genomes and their relationship to other cardioviruses. All SAFV genomes used for phylogenetic analysis are identified by their genotype (SAFV-# ), the name used in their original publication and the country where the genomes were identified. Genomes reported in this study are marked with an asterisk. The tree was constructed in MEGA4 using the maximum composite likelihood method to calculate evolutionary distances. Bar, 0.05 base substitutions per site. One thousand bootstrap resamplings were performed to assess statistical support.
from the family Picornaviridae, such as coxsackie A viruses (S. van der Sanden, H. van der Avoort & M. Koopmans, unpublished data), indicating endemic circulation in the Netherlands. Based on a virus-neutralization assay, it has been shown that SAFV-3 infection is indeed widespread in humans in at least three continents (Europe, Africa and Asia; Zoll et al., 2009) . Consistent with the hypothesis of endemic circulation, infection seems to occur in early life, as 92-98 % of a group of 150 individuals between 4 and 40 years old from the Netherlands had neutralizing antibodies against SAFV-3 (Zoll et al., 2009) . Seroprevalence data also indicated that SAFV-3_NL2007 or a related virus has been present in the Netherlands for at least 10 years (Zoll et al., 2009) , confirmed by the identification of SAFV_NL1999-590 (Fig. 2) . In the USA, it has been shown that 91 % of adults carry antibodies against SAFV-2, with 80 % of studied individuals generating neutralizing antibodies against this genotype (Chiu et al., 2010) .
Although SAFV infection is highly prevalent, the pathogenicity of this virus remains unknown. SAFV has been detected in stool and respiratory-secretion samples from children with gastroenteritis (Chiu et al., 2008; (Abed & Boivin, 2008; Chiu et al., 2008) and non-polio acute flaccid paralysis , as well as in asymptomatic individuals Chiu et al., 2008; Xu et al., 2009; Zoll et al., 2009) . In several cases, SAFV has been detected in addition to other viruses known to cause gastroenteritis, thus hindering interpretation regarding SAFV infection and observed pathology (Chiu et al., 2008; Drexler et al., 2008; Ren et al., 2009) . SAFV-2 has recently been linked to infection in a child with diarrhoea and vomiting, based on an acute seroconversion event supporting an association between this virus and diarrhoeal disease (Chiu et al., 2010) . Although SAFV-3 was the only viral agent identified in five of 15 of the unexplained cellculture samples in this study, it cannot be concluded that these viruses were causing illness or clinical symptoms. It is well-known that enteroviruses may manifest illness in a minority of infected persons, but this does not mean that infections are trivial. Polio, for instance, develops in ,1 % of infected persons, but is a debilitating disease that results in lifelong disabilities. Therefore, further research is needed to unravel the possible role of SAFV in human illness.
Sequence-independent methods are becoming more important to identify emerging viruses in public-health Fig. 2 . Similarity-plot analysis of SAFV genomes identified in the Netherlands and Germany, using SAFV-3_NL2007 (GenBank accession no. FM207487) as the query sequence. Analysis was performed in SimPlot version 3.5.1 using a window size of 400 bp, a step size of 20 bp and an empirical transition to transversion ratio. Sequences or groups marked with an asterisk indicate sequences reported in the present study (GenBank accession nos HM181996-HM181999). Sequences from Germany include the SAFV-2 strain D/2229 (GenBank accession no. EU681176) and SAFV-3 strains D/2223 and D/2273 (GenBank accession nos EU681178 and EU681179, respectively). Fig. 3 . Neighbour-joining phylogenetic tree of SAFV VP1 sequences. All SAFV sequences used for phylogenetic analysis are identified by their genotype (SAFV-# ), the name used in their original publication and the country where the sequences were identified. Sequences reported in this study are marked with an asterisk. The tree was constructed in MEGA4 using the maximum composite likelihood method to calculate evolutionary distances. Bar, 0.05 base substitutions per site. One thousand bootstrap resamplings were performed to assess statistical support. monitoring efforts (Abed & Boivin, 2008 
METHODS
Clinical specimens. All clinical specimens reported in this study were collected through the EVS programme in the Netherlands. The goal of this programme is to monitor poliovirus circulation and ensure its eradication from the Netherlands. Although 90 % of enterovirus infections are asymptomatic, these infections can result in a broad spectrum of clinical symptoms (Zaoutis & Klein, 1998) . Therefore, the EVS collects samples from patients with a variety of clinical manifestations such as meningitis, hepatitis, respiratory illness and gastrointestinal disorders. As virus shedding of both symptomatic and asymptomatic patients occurs through faeces, most of the samples collected through the EVS programme are stool specimens, which provide information about the general circulation of enteroviruses. The surveillance in its current form was started after a poliovirus type 3 outbreak in 1992 -1993 (Conyn-van Spaendonck et al., 1996 Oostvogel et al., 1994) . In order to detect polioviruses, all samples were initially tested for a broad range of enteroviruses in routine virological laboratories (Nix et al., 2006; Oberste et al., 1999) , which are linked to academic hospitals or to regional public-health centres throughout the entire country. For enterovirus surveillance, clinical samples were cultured on combinations of cell lines used routinely in the different laboratories, including human rhabdomyosarcoma (RD), tertiary monkey kidney (tMK), rhesus monkey kidney (LLC-MK2), Vero, HEp-2, human epithelial carcinoma (HeLa), human embryonic lung fibroblast (Gabi) and various human fibroblast cell lines, and confirmed as enteroviruses by local laboratories. Cell-culture samples that exhibited CPE but tested negative for enteroviruses or were not typed genetically were submitted to the RIVM for virus identification and typing by PCR. Between 1994 and 2007, a total of 1834 cell-culture isolates collected throughout the Netherlands were submitted to RIVM for analysis.
Systematic analysis of cell-culture isolates from EVS samples at RIVM. Cell-culture isolates submitted to RIVM were passaged once, and subsequently tested using PCR assays for enteroviruses (Nix et al., 2006; Oberste et al., 1999) , followed by parechoviruses . Samples that remained negative for enteroviruses and parechoviruses were screened using a broad range of PCR assays for noroviruses, rotaviruses A, B and C, adenoviruses, astroviruses, sapoviruses, vesiviruses, reoviruses, a generic PCR that detects both enteroviruses and rhinoviruses, hepatitis A and E viruses, influenza A and B viruses, Aichi virus, coronaviruses 229E, NL63 and OC43, human respiratory syncytial viruses A and B and human metapneumovirus, as described previously (Svraka et al., 2007 (Svraka et al., , 2009a van der Sanden et al., 2008; van Gageldonk-Lafeber et al., 2005) . Samples that tested negative in all assays but showed consistent CPE were processed for metagenomic sequencing (Tables 1 and 2 ). Information regarding sample description for these unexplained cell cultures and associated patient clinical symptoms is given in Table 2 .
Virus-particle purification and metagenomic sequencing. Virus particles were purified from selected cell cultures prior to metagenomic sequencing. For this purpose, cell-culture samples were vortexed vigorously for 2 min. A 1 ml aliquot was collected and mixed with 1 ml SM buffer [0.1 M NaCl, 50 mM Tris/HCl (pH 7.4), 10 mM MgSO 4 ], vortexed once again and filtered through a 0.22 mm Sterivex filter (Millipore). The filtrate (i.e. virus fraction) was treated with 20 % (v/v) chloroform, followed by treatment with DNase I (2.5 U ml 21 ) and RNase (0.25 U ml 21 ) to remove free nucleic acids. If no viruses were detected after this purification procedure, the purification was repeated without chloroform and treated with only DNase I (2.5 U ml 21 ) to recover enveloped viruses. The methods used for virus purification for each of the samples are summarized in Table  2 . Prior to extracting total viral nucleic acids, EDTA (20 mM final concentration) was added to a 200 ml aliquot of purified virus particles to chemically inactivate nucleases. For analysis of RNA viruses, total RNA was extracted from virus particles by using a Qiagen RNeasy Mini kit, followed by randomly primed RNA amplification with a Transplex Whole Transcriptome Amplification (WTA) kit (Sigma-Aldrich) according to the manufacturer's protocol using 50 and 65 PCR cycles. For analysis of DNA viruses, total viral nucleic acids were extracted using a QIAamp MinElute Virus Spin kit (Qiagen), followed by random amplification using a GenomiPhi V2 DNA Amplification kit (GE Healthcare) according to the manufacturer's protocol. GenomiPhi products were amplified further using a Whole Genome Amplification (WGA) kit (Sigma-Aldrich).
As it was unknown whether the selected cell-culture samples contained DNA or RNA viruses, WTA and WGA products were examined on a 2 % agarose gel, and positive reactions (defined as a smear between 200 and 400 bp) were purified by using an UltraClean PCR Clean-Up kit (MO BIO Laboratories Inc.). The purified products were cloned into competent Escherichia coli cells using the TOPO TA system (Invitrogen) and sequenced. To identify the different viruses in the cell-culture samples, approximately 48 clones were selected from each sample for sequencing. The sequenced fragments were compared against the GenBank non-redundant (nr) nucleotide database through tBLASTx (E-value ,0.001) (Altschul et al., 1997) .
Genome completion of SAFV. WTA fragments sequenced from four samples had significant similarities to SAFV. In order to complete the genome of the SAFV-like viruses, WTA fragments were assembled against the SAFV genome with the highest similarities to the sequenced WTA fragments (i.e. SAFV-3_NL2007; GenBank accession no. FM207487). The assembly was performed by using the Sequencher software (version 4.1; GeneCodes), using the assembly algorithm for dirty data with optimization for gap alignment, 70 % minimum match percentage and a minimum overlap of 10 bp. As WTA fragments did not overlap into a complete genome, the assembly was used to design primers for genome walking based on the consensus sequence between WTA fragments and SAFV-3_NL2007. GTGTTTGTGGCCGTGTTTC  1418F  TGAACATTCTTGGTAGTGCTG  49  2480R  TTCTCTTTTTGTTAGAGTCC  2400F  CACCACCGTTCCTGTTTACG  49  3860R  CCAAAGCCAGGGATTTCATA  5157F  GCCAAATGGTCTCAAGTACA  49  6450R  ATACCGCCACCACCAGC  6600F  CGCAGAACAGTAGCACACC  49  7480R  GGTTAAGTGTAATGCTGCTC  7124F  ACTGTTAGGGCGTTTTGCATC  49  8125R  TTTTTTTTTTTTTTGTTCTCATTTCCAA  HM181997, HM181998, HM181999  1F  TTTCAAAGGGGGCCCTG  49  650R  CACTTATTGAGAGACGGA  528F  GGTCTAAGCCGCTYGGAAT  60  1092R  CAAYRGCWGTGCAAAKAGGGCACAC  1087F  CRKWTKTGTGCCCTMTTTGCACWGCYRTTG  60  1585R  ASAAACGACCAACWGTKGATT  1418F  TGAACATTCTTGGTAGTGCTG  49  2480R  TTCTCTTTTTGTTAGAGTCC  2300F  GTCAGGGAACATGCTGGAAC  49  2790R  TCCCAAATGGCGTAAGT  2690F  TGGAGCAGGAGAACCCAAA  49  3750R  TTTGGTGTCTTGTGGGTTTG  3670F  TCAGTACATTACAGATACAA  44  4100R  AAGTAGAAAATCCATGATCG  3750F  CAAACCCACAAGACACCAAA  49  5050R  GCGGCCAAATGAGAGTTTAG  5175F  TTGTCAAATGGTTTCAAGTAC  44  6470R  GCATTGCGTACACAGC  6470F  GCTGTGTACGCAATGC  49  7190R  CTGAGCCAAGATCCAAACCA  6720F  CGTAGACCAGGTCGCTTTCT  44  7570R  AGTCATCACCATAAGATAAA  7570F  TTTATCTTATGGTGATGACT  44  8125R TTTTTTTTTTTTTTGTTCTCATTTCCAA *Primer number indicates approximate nucleotide position in reference genome SAFV-3 (GenBank accession no. FM207487). DAnnealing temperature. All PCRs were performed with a touchdown program to decrease the annealing temperature incrementally by 0.2 uC each cycle. RACE 59 indicates gene-specific primers used for the 59 RACE system (Invitrogen) and nested reactions according to the manufacturer's instructions. cDNA was produced from RNA extracted from purified virus particles by using a Synthesis SuperScript III reverse transcription kit (Invitrogen) with random primers. Each PCR was performed in a 50 ml reaction containing 4 ml cDNA, 16 REDTaq PCR buffer (Sigma-Aldrich), 1 mM each primer (Table 3) , 0.2 mM dNTPs and 1 U REDTaq DNA polymerase (Sigma-Aldrich). Each PCR proceeded at 94 uC for 5 min, followed by 50 cycles of 94 uC for 1 min, annealing temperature (Table 3) for 45 s, and 72 uC for 2 min and a final extension at 72 uC for 10 min. The 59-UTR region was verified with the 59 RACE system (Invitrogen) using gene-specific primers (Table 3) according to the manufacturer's suggested protocol for high-G+C transcripts. SAFV genome sequences have been submitted to GenBank under accession numbers HM181996-HM181999.
Phylogenetic analysis of identified SAFV isolates. The SAFV genome sequences were used for phylogenetic analysis (Fig. 1) . All alignments were performed by using the CLUSTAL W algorithm (Thompson et al., 1994) and BLOSUM62 as the similarity matrix in BioEdit version 7.0.9.0 (Hall, 1999) . A neighbour-joining phylogenetic tree was constructed in MEGA4 (Tamura et al., 2007) , using the maximum composite likelihood method to calculate evolutionary distances. All gaps and missing data were eliminated from the dataset and 1000 bootstrap resamplings were performed to assess statistical support.
A similarity-plot analysis showing the relationship among the detected SAFV sequences and previously reported genomes was performed by using SimPlot software, version 3.5.1 (Lole et al., 1999) . The following parameters were used to calculate the similarity plot: 400 bp window size, 20 bp step size and an empirical transition to transversion ratio. Sequences that originated from the same region and were 98-99 % identical at the nucleotide level were grouped for the SimPlot analysis.
SAFV screening of additional unexplained samples from EVS.
The original cell-culture isolates examined for this study were collected through the EVS programme between 1994 and 2007. To further assess the prevalence of SAFV in unexplained cell-culture samples, eight additional unidentified cell-culture isolates collected between 2008 and 2009 were tested by using a PCR assay targeting the VP1 region of SAFV . The VP1 region is the most diverse protein of picornaviruses and has been used to classify different SAFV genotypes . For the PCR assay, cDNA was obtained from randomly primed reverse transcription of total RNA from cell cultures using a SuperScript III reverse transcription kit (Invitrogen).
The RT-PCR was prepared by adding 2.5 ml reverse transcription mixture with random primers to 22.5 ml PCR mixture containing 12.5 ml HotStarTaq mastermix (Qiagen), 1.25 ml forward and reverse primers (10 pmol ml 21 ) and 7.5 ml H 2 O. For the VP1 region, VP1F1 (59-ACWCTTGGTTTCDGGHGG-39) and VP1R1 (59-TCGCCC-ATRCASACRAGRA-39) primers were used in the first round of nested PCR, while VP1F2 (59-GACTTYACYCTBAGAATGCC-39) and VP1R2 (59-ACTGTTCTAYCRTGAACTTTGTA-39) were used in the second round . The PCR proceeded as follows: denaturation at 95 uC for 15 min, four cycles of amplification at 95 uC for 1 min, 55 uC for 1 min and 68 uC for 1 min 30 s, followed by 35 cycles of amplification at 95 uC for 30 s, 52 uC for 30 s and 68 uC for 1 min 30 s, then a final extension at 68 uC for 10 min. A 2.5 ml sample from the first-round PCR was used as template for the nested PCR. The same PCR mixture and conditions were used for both rounds of PCR .
Sequences from the SAFV VP1 PCR products, along with publicly available sequences that were previously classified into SAFV genotypes, were used for phylogenetic analysis. A neighbour-joining tree was constructed in MEGA4, using the same parameters that were used to construct the phylogenetic tree of full-length SAFV genomes (Fig. 3) .
